share_log

Clearmind Medicine | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SEC announcement ·  May 8 04:06
Summary by Futu AI
Clearmind Medicine Inc., a clinical-stage biotech company, has announced the signing of an exclusive patent licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. This agreement, announced on May 7, 2024, grants Clearmind exclusive global rights to develop, manufacture, and commercialize novel psychedelic compounds for the treatment of PTSD and other mental health conditions. The compounds, invented by Professors Rami Yaka, Ahmed Masaewa, and Avi Priel, are seen as a significant advancement in the treatment of PTSD, a market projected to grow to $27.37 billion by 2033. Clearmind's CEO, Dr. Adi Zullof-Shani, expressed optimism about the potential of these compounds to address urgent mental health care needs. The agreement includes milestone payments, royalties on future sales, and commitments to protect intellectual property rights. Clearmind, listed on Nasdaq and the Frankfurt Stock Exchange, is focused on developing psychedelic-derived therapeutics for underserved health problems, including alcohol use disorder.
Clearmind Medicine Inc., a clinical-stage biotech company, has announced the signing of an exclusive patent licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. This agreement, announced on May 7, 2024, grants Clearmind exclusive global rights to develop, manufacture, and commercialize novel psychedelic compounds for the treatment of PTSD and other mental health conditions. The compounds, invented by Professors Rami Yaka, Ahmed Masaewa, and Avi Priel, are seen as a significant advancement in the treatment of PTSD, a market projected to grow to $27.37 billion by 2033. Clearmind's CEO, Dr. Adi Zullof-Shani, expressed optimism about the potential of these compounds to address urgent mental health care needs. The agreement includes milestone payments, royalties on future sales, and commitments to protect intellectual property rights. Clearmind, listed on Nasdaq and the Frankfurt Stock Exchange, is focused on developing psychedelic-derived therapeutics for underserved health problems, including alcohol use disorder.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.